By sponging miR‐128 and subsequently dysregulating the RAS/MAPK signalling pathway, LINC01614 emerges as a key player in astrocytoma progression and a promising therapeutic target. Here, LINC01614 is linked to astrocytoma (excluding glioblastoma).